High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta

被引:31
作者
Cabral, WA [1 ]
Marini, JC [1 ]
机构
[1] NICHHD, Bone & Extracellular Matrix Branch, Sect Heritable Disorders Bone, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1086/383252
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Individuals with mosaicism for the autosomal dominant bone dysplasia osteogenesis imperfecta (OI) are generally identified by having more than one affected child. The mosaic carriers have both normal and mutant cell populations in somatic and germline tissues but are unaffected or minimally affected by the type I collagen mutation that manifests clinically in their heterozygous offspring. We determined the proportion of mutant osteoblasts in skeletal tissue of two mosaic carriers who each have a COL1A1 mutation in a high proportion of dermal fibroblasts. Both carriers had normal height and bone histology; the first carrier had normal lumbar spine measurements (L1 - L4), as determined by dual-energy x-ray absorptiometry (Z = +1.17). In cultured cells from the first carrier, studied by labeled PCR and single-cell PCR over successive passages, the collagen mutation was present in 85% of fibroblasts and 50% and 75% of osteoblasts from her right iliac crest and left patella, respectively, with minimal selection. The second carrier was studied by PCR amplification of DNA from autopsy paraffin blocks. The proportion of heterozygous cells was 40% in calvarium, 65% in tracheal ring, and 70% in aorta. Thus, in OI, substantially normal skeletal growth, density, and histology are compatible with a 40% - 75% burden of osteoblasts heterozygous for a COL1A1 mutation. These data are encouraging for mesenchymal stem-cell transplantation, since mosaic carriers are a naturally occurring model for cell therapy.
引用
收藏
页码:752 / 760
页数:9
相关论文
共 37 条
[21]  
Lund AM, 1996, EUR J HUM GENET, V4, P39
[22]   Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/IV [J].
Lund, AM ;
Nicholls, AC ;
Schwartz, M ;
Skovby, F .
ACTA PAEDIATRICA, 1997, 86 (07) :711-718
[23]   Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep [J].
Mackenzie, TC ;
Flake, AW .
BLOOD CELLS MOLECULES AND DISEASES, 2001, 27 (03) :601-604
[24]   Osteogenesis imperfecta rehabilitation and prospects for gene therapy [J].
Marini, JC ;
Gerber, NL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (09) :746-750
[25]  
Marini JC, 1999, NAT MED, V5, P466, DOI 10.1038/8326
[26]  
MARINI JC, 2001, MANAGEMENT GENETIC S, P281
[27]   Approaches for skeletal gene therapy [J].
Niyibizi, C ;
Wallach, CJ ;
Mi, ZB ;
Robbins, PD .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2002, 12 (03) :163-173
[28]   Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging [J].
Oyama, M ;
Tatlock, A ;
Fukuta, S ;
Kavalkovich, K ;
Nishimura, K ;
Johnstone, B ;
Robbins, PD ;
Evans, CH ;
Niyibizi, C .
GENE THERAPY, 1999, 6 (03) :321-329
[29]   Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta [J].
Pereira, RF ;
O'Hara, MD ;
Laptev, AV ;
Halford, KW ;
Pollard, MD ;
Class, R ;
Simon, D ;
Livezey, K ;
Prockop, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) :1142-1147
[30]   Marrow stromal cells as steam cells for nonhematopoietic tissues [J].
Prockop, DJ .
SCIENCE, 1997, 276 (5309) :71-74